<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081938</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_04572</org_study_id>
    <secondary_id>U1111-1116-9777</secondary_id>
    <nct_id>NCT01081938</nct_id>
  </id_info>
  <brief_title>Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition</brief_title>
  <official_title>National, Phase IV, Multicentric, Open Label, Comparative Study to Evaluate the Efficacy and Safety of Insulin Glargine Plus Glulisine and Sliding Scale Plus Glulisine in Hospitalized Patients With Diabetes Metabolism Type II Under Enteral Nutrition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      1- Proportion of patients with mean daily glycemia &lt;140mg/dL during the period of 7 days of
      treatment with glargine plus supplemental glulisine versus patients with glulisine sliding
      scale.

      Secondary Objective:

        1. Incidence of moderate hyperglycemia (&gt;140mg/dL) during the treatment period.

        2. Incidence of hypoglycemia (&lt;60mg/dL and &lt; 40mg/dL) during the treatment period.

        3. Incidence of severe hyperglycemia (&gt;400mg/dL) during the treatment period.

        4. Total dose of insulin and correction dose in each group.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment challenges
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycaemic parameters assessment</measure>
    <time_frame>During the period of 7 Days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate and severe hyperglycemia</measure>
    <time_frame>During the period of 7 Days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic, nocturnal and severe hypoglycemias</measure>
    <time_frame>During the period of 7 Days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin Glargine + Insulin Glulisine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Glulisine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE</intervention_name>
    <description>Pharmaceutical form: Lantus® (100 U/ml)
Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.
Dose regimen: Single daily dose of Insulin Glargine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLULISINE</intervention_name>
    <description>Pharmaceutical form: Apidra® (100 U/ml)
Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device
Dose regimen:
Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Men and women with type 2 diabetes that will need enteral nutrition with carbohydrate
             content.

          -  Glycemia &gt;140mg/dL and &lt; 400mg/dL at admission on the ward.

          -  Informed consent (patient or legally authorized representative)

        Exclusion criteria:

          -  Hypersensibility to insulin glargine or glulisine, or any other component of the
             insulin formulation.

          -  Use of investigational medications during the last 12 months or use of any
             investigational insulin preparation during the last 4 months.

          -  History of diabetic ketoacidosis or hyperosmolar hyperglycaemic state or ketonuria.

          -  Subjects with conditions that are expected to need surgery or intensive care unit
             (ICU)admission based on discussions with the treatment team and attending physician.

          -  Pregnancy.

          -  Severe hepatic disease or active hepatitis.

          -  Cardiac failure class III or IV (Classification de la New York Heart
             Association:NYHA).

          -  Diagnosed advanced autonomic neuropathy.

          -  Diagnosed cancer.

          -  Active infection.

          -  Current therapy with steroids.

          -  Patients with recognized or suspected endocrine disorders associated with increased
             insulin resistance, acromegaly, or hyperthyroidism.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-007</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-011</name>
      <address>
        <city>Curitiba</city>
        <zip>80420-011</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-005</name>
      <address>
        <city>Joinville</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-001</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-004</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-006</name>
      <address>
        <city>São José do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-010</name>
      <address>
        <city>São Paulo</city>
        <zip>01232-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-008</name>
      <address>
        <city>São Paulo</city>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-003</name>
      <address>
        <city>São Paulo</city>
        <zip>01323-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Investigational Site Number 076-009</name>
      <address>
        <city>São Paulo</city>
        <zip>01323-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

